Skip to main content
OpenTrials
Completed

NCT Number: NCT04670614

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

This is a prospective, randomized, blinded, sham controlled regional anesthetic (supra-orbital and infra-orbital nerve block) pain study to compare the systemic postoperative pain medication requirements in patients having Trans-sphenoidal Pituitary surgery. The patients will receive general anesthesia +/- regional anesthesia for trans-sphenoidal pituitary surgery and systemic pain medication during the intra-operative and postoperative (6hrs) period. The amount of systemic pain medication requirements will be compared between those patients receiving regional and general anesthesia versus general anesthesia alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCSF Moffitt Long Hospital

San Francisco, California, 94143, United States

About this study

Combined regional and general anesthesia for surgery is known to provide superior pain control in the peri-operative period (intra and post-operative). Of particular interest in neurosurgery are more rapid patient awakening and earlier ability to perform adequate post-operative neurological exam. In addition to this, regional anesthesia can decrease the total amount of systemic pain medications necessary and thus decrease their associated side effects. Consequently, less systemic pain medications can benefit the patient in many ways.

By modifying the postop pain regime to include intraoperative regional anesthesia, there could be increased patient satisfaction, and significant economic gains to the hospital through a more streamlined, shorter, more pleasant hospital course for the patient. Patients who have this trans-sphenoidal pituitary surgery are usually same day admission patients who, following their surgery, are admitted for up to 24 hours postoperatively. Usually prolonged admissions result from headache and nausea +/- vomiting. Etiology of the headache is likely multifactorial. One theory is that stimulation of the peripheral trigeminal (Cranial Nerve Number V) fibers in the V1 and V2 distribution of the face by the surgical endoscope and surgical trauma may lead to release of inflammatory mediators and post-operative migraine. It has been shown that repetitive injection of local anesthetics in the distribution of supra-orbital nerve V1 and infra-orbital nerve V2 can decrease the incidence of chronic idiopathic migraine headaches not related to surgery. By administering regional anesthesia to the patient intra-operatively during their general anesthetic for the surgery, pain scores may be reduced, PONV (postoperative nausea and vomiting) decreased, and hospital stay shortened.This study will be examining the use of regional anesthesia (infra-orbital and supra-orbital nerve blocks) combined with general anesthesia versus general anesthesia to observe the systemic opioid consumptions of adult transsphenoidal pituitary surgery patients. Secondary endpoints of the study will be: (1) presence of PONV, (2) time in PACU (post anesthesia care unit) and finally, (3) duration of hospital stay until discharge.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult age between 18 and 65
  • American Society of Anesthesiology (ASA) 1-2
  • Elective pituitary tumor surgery, tumor less than or equal to 2 cm diameter within the sella and no cavernous
  • sinus invasion
  • Single surgeon, Dr. Kunwar
  • Male and female patients
  • English speaking
  • Informed consent
  • Not on chronic pre-opertaive pain medications (non-narcotics) in the last 1 week prior to surgery
  • No opioid pain medications pre-op in the last 1 month before surgery
  • No abuse of recreational drugs (cocaine, methamphetamines, THC (tetrahydrocannabinol), opioids/heroin)
  • No herbal medications for pain in the 1-month prior to surgery

Exclusion criteria

  • Age less than 18 years
  • Non-English speaking
  • Allergy to: Ropivicaine
  • Chronic pain condition, including idiopathic migraine as defined by the ICHD (International Classification of Headache Disorders) II criteria, requiring the use of pain medications
  • Inability to comprehend or adhere to study protocol

Treatment and study plan

Nerve Block with ropivicaine 0.5% Injectable Solution

Procedure

Peripheral nerve blocks using 0.5% ropivicaine

Nerve Block with Placebo sham control of 0.9% Normal Saline

Procedure

Peripheral Nerve Block with placebo 0.9% normal saline

Primary outcomes

  1. 6 hour post-operative Morphine Requirements in milligrams (mg)

    Time frame: 6 hours post-op

    Systemic Intravenous (IV) morphine opioid consumption in mg in 2 groups during first 6 hours post-operatively (regional + general versus only general anesthesia)

Secondary outcomes

  1. Pain exposure postoperative for 6 hours

    Time frame: 6 hours

    Pain score out of max 10 (Scale 0-10). "O" (no Pain) and "10" (worst possible pain)

  2. Nausea and/or vomiting for 6 hours postoperatively

    Time frame: 6 hours

    Nausea score out of max 10 (Scale 0-10)."O" (no nausea) and "10" (worst nausea possible). Presence of vomiting is minimum score of 5/10.

  3. Time to discharge from Post anesthesia care unit (PACU) in minutes

    Time frame: post-operative period measured in minutes up to 120 minutes

    Time patient spends in PACU from entry time until discharge to the floor in minutes

  4. Time to discharge from hospital in minutes

    Time frame: post-operative time up to 36 hours

    Time measured in minutes from surgery start to discharge from the hospital

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Acronym: SION

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 17, 2020
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.